Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palazestrant monotherapy versus standard endocrine therapy for ER-positive, HER2-negative advanced or metastatic breast cancer
NL-OMON60969Phase 3Active, not recruiting
- Sponsor
- Olema Oncology
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of palazestrant in breast cancer (4 arms), sponsored by Olema Oncology. Primary endpoints: Safety and tolerability and BIRC-assessed progression-free survival. Started Aug 2024; status: active, not recruiting.
02
Drugs
palazestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON60969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60969.